Epoetin Alfa vs BYM338
Head-to-head comparison of Epoetin Alfa (Recombinant human erythropoietin alfa) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Epoetin Alfa | BYM338 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Recombinant human erythropoietin alfa | Bimagrumab (BYM338) |
| Molecular Weight | ≈30,400 Da | ~148 kDa |
| Half-Life | ~4-13 h IV; ~20-30 h SC | ~2-3 weeks |
| Amino Acids | 165 | N/A |
| Typical Dose | 50-100 IU/kg SC 3x weekly or 40,000 IU SC weekly | 10-30 mg/kg IV in trials |
| Route | Subcutaneous/IV | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 320 | 140 |
| Research Status | Clinical | Clinical |
Epoetin Alfa Benefits
- ✓raises hemoglobin
- ✓increases oxygen-carrying capacity
- ✓may increase VO2 max
- ✓improves time-to-exhaustion
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Epoetin Alfa Dosing
50-100 IU/kg subcutaneous 3x weekly|40,000 IU subcutaneous weekly|Titrate to hemoglobin target under medical supervision
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Epoetin Alfa Side Effects
- ⚠hypertension
- ⚠thrombosis
- ⚠polycythemia
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Epoetin Alfa
Human studies in anemia and performance-related settings show that increasing red-cell mass can improve aerobic capacity and endurance. It remains heavily regulated because excessive erythropoiesis raises thrombotic and cardiovascular risk.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.